EQ — Equillium, Inc.
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Market
- Employees: 35
- Website: https://equilliumbio.com
Latest SEC filings for EQ
- 10-Q — 2026-08-13
- 8-K — 2026-08-13
- SCHEDULE 13G/A — 2026-08-12
- 8-K — 2026-05-29
- 8-K — 2026-05-13
- 10-Q — 2026-05-13
- EFFECT — 2026-04-17
- ARS — 2026-04-15
- S-3 — 2026-04-07
- S-3 — 2026-04-07
Latest EQ news
- — Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference (globenewswire.com)
- — Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504 (globenewswire.com)
- — Equillium Announces Poster Presentations at the 7th International AHR Conference (globenewswire.com)
- — Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
- — Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504 (marketbeat.com)
Educational tool only — not investment advice.